Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
Pharmaceutical
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Supply Obeticholic Acid raw Materials Powder
Product Overview:
Obeccholic acid is developed by Intercept Pharmaceutical Company in the United States, and its compound patent was applied for in the United States in 2001, patent number US7138390, and has not yet applied for compound patent in China. Obeccholic acid is the first drug developed in 20 years to treat cholestatic liver disease in patients who do not respond adequately to ursodeoxycholic acid or cannot tolerate it.
Supply Obeticholic Acid raw Materials Powder Attributes
CAS:459789-99-2
MF:C26H44O4
MW:420.63
EINECS:810-245-2
Specification: 99% min Obeticholic Acid Powder
Sample:Obeticholic Acid Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Supply Obeticholic Acid raw Materials Powder Details
Obeticholic Acid Powder Usage and Synthesis.
Obeticholic Acid, also known as 6-ethyl goosenodeoxycholic acid, is a novel derivative of goosenodeoxycholic acid (CDCA) in human primary bile acids and a natural ligand of farnesate derivative X receptor (FXR). Obecholic acid is a farnesol X receptor agonist, which indirectly inhibits cytochrome 7A1 (CYP7A1) gene expression by activating farnesol X receptor. Because CYP7A1 is a rate-limiting enzyme for cholic acid biosynthesis, obecholic acid can inhibit cholic acid synthesis and is used in the treatment of primary biliary cirrhosis and non-alcoholic fatty liver disease.
Uses of Obeticholic Acid.
Obeccholic acid tablets can inhibit the synthesis of cholic acid, promote bile secretion and reduce portal hypertension, and can play a role in the treatment of primary biliary cirrhosis, non-alcoholic fatty liver, primary sclerosing cholangitis and other diseases when prescribed by doctors.
Obecholic acid tablet is a farnitol receptor agonist, which can indirectly inhibit the expression of cytochrome gene, thus inhibiting the synthesis of cholic acid, promoting bile secretion and reducing portal hypertension. Obeccholic acid tablets are often used to treat primary biliary cirrhosis, and can also be used to treat nonalcoholic fatty liver and primary sclerosing cholangitis. This product can be used alone or in combination with ursodeoxycholic acid, but patients with complete intestinal obstruction should contraindicate this product. The therapeutic effect of obecholic acid tablets is good, but some people will have adverse reactions after application, common adverse reactions include diarrhea, nausea, vomiting, abdominal pain and so on. However, these symptoms are usually temporary and usually resolve on their own after stopping the drug.
During the use of aubecholic acid tablets, regular follow-up visits should be made with a doctor to ensure the effectiveness and safety of treatment.
Pharmacological action of Obeticholic Acid.
PBC is a chronic cholestasis caused by bile duct dysplasia or bile acid metabolism disorder, which causes lipid dissolution of cell membrane, permeability change, cell content flow out, and eventually progress to liver fibrosis and cirrhosis. At present, ursodeoxycholic acid (URsodeoxycholic acid) is the main drug used in clinical treatment of PBC. Ursodeoxycholic acid stimulates hepatobiliary secretion through intracellular signaling molecule mitogen-activated protein kinase (MAPK) pathway, and protects epithelial cells from bile acid destruction.
Product Method of Bulk Obeticholic Acid Powder.